Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05205811
Other study ID # BuZonE 2
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 14, 2021
Est. completion date June 30, 2024

Study information

Verified date November 2023
Source Rose Research Center, LLC
Contact Derek Mercedes
Phone 704-350-2999
Email derek.mercedes@roseresearchcenter.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline information on the use of combustible cigarettes. All participants enrolled in the study will receive a JUUL e-cigarette at Visit 2 for ad libitum use. After the first week of e-cigarette use (at Visit 3), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with either zonisamide (100 mg daily) or placebo (group 1 and group 2 respectively), or placebo for both medications (group 3) in addition to continued use of the e-cigarette. At each visit, participants will receive enough study drugs (or placebos) and e-cigarettes to last until their next study visit. The combination of zonisamide and bupropion use will continue until Visit 6 (7 weeks of treatment), and e-cigarette use will continue until the end of treatment (Visit 7).


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date June 30, 2024
Est. primary completion date February 28, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: 1. Has signed the ICF and is able to read and understand the information provided in the ICF. 2. Is 21 to 65 years of age (inclusive) at screening. 3. Smokes at least 10 commercially available cigarettes per day (no brand restrictions), for the last 12 months. 4. Has an expired air CO reading of at least 10 ppm at screening. 5. Is interested in switching to an electronic cigarette. 6. Is willing and able to comply with the requirements of the study. 7. Owns a smartphone with text message and data capabilities compatible with necessary surveys. Exclusion Criteria: 1. Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, ECG, concomitant medications and medical history). 2. Has a PHQ-9 score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening. 3. Has plans to use an FDA-approved smoking cessation product during the study. 4. Has high blood pressure (systolic > 150 mmHg or diastolic >95 mmHg) at screening. 5. Has body mass index (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2. 6. Has coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure. 7. Has received psychotherapy or behavioral treatments potentially impacting symptoms of depression, anxiety, or nicotine withdrawal within 30 days of screening, or during the study. 8. Is taking antidepressants, psychoactive medications (e.g. antipsychotics, benzodiazepines, hypnotics) or medications that prolong QTc. 9. Has used any of these products in the past 30 days: 1. Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, methamphetamines, or opiates); 2. Experimental (investigational) drugs that are unknown to participant; 3. Chronic opiate use. 10. Has used smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black & Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening. 11. Has a plan to use an FDA-approved quit-smoking treatment in the next 30 days. 12. Is pregnant or nursing (by self-report) or has a positive pregnancy test. 13. Enrollment requirements met.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bupropion
Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
Zonisamide
Zonisamide (100 mg/daily) for 7 weeks.
Placebo bupropion
Placebo bupropion for 7 weeks.
Placebo zonisamide
Placebo zonisamide for 7 weeks.
Other:
E-cigarette
e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.

Locations

Country Name City State
United States Rose Research Center Charlotte North Carolina
United States Rose Research Center Raleigh North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Rose Research Center, LLC Foundation for a Smoke Free World INC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Tolerability of study drugs as measured by frequency of drug termination or drug non-adherence The frequency of drug termination or non-adherence prior to Week 8 will be tabulated for each condition. Adverse effects will also be tabulated for each condition, including the following adverse effects of special interest (AESIs): insomnia, agitation, dry mouth, somnolence, headache, nausea, constipation, diarrhea, dizziness or loss of appetite. Baseline, Week 1, Week 2, Week 4, Week 8
Other Seven-day point abstinence at 6 months post-switch Seven-day point abstinence at 6 months post-switch will be assessed by self-report and confirmed by exhaled carbon monoxide (CO) < 5 ppm. 6 Months post Switch Day
Primary Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by Exhaled carbon monoxide (CO) Exhaled carbon monoxide (CO) < 5 ppm at the end of drug treatment After 8 weeks
Primary Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by change in Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) Baseline, Week 8, Week 12
Primary Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by change in self-report of daily cigarette and e-cigarette use Self-report of daily cigarette and e-cigarette use Daily from Week 2 to Week 12
Secondary Change in Smoking withdrawal symptoms Smoking withdrawal symptoms will be collected using a questionnaire developed by Drs. Shiffman and Jarvik (1976), which assesses craving for cigarettes, negative mood, arousal, missing the habit of smoking, changes in appetite and somatic symptoms and a seven-point scale (from 1-Not at All to 7-Extremely). Higher scores indicate more withdrawal symptoms. Baseline, Week 1, Week 2, Week 4, Week 8, Week 12
Secondary Change in Rewarding and aversive effects of smoking and e-cigarette use The mCEQ-E will be utilized to assess the degree to which participants experience the reinforcing of smoking, providing five subscale scores: smoking satisfaction (satisfying, tastes good,enjoy smoking), psychological rewards (calms down, more awake, less irritable, helps concentrate, reduces hunger), aversion (dizziness, nauseated), enjoyment of respiratory tract sensations (single-item assessment), craving reduction (single-item assessment). Participants will be asked to assess the 12 items of the questionnaire on a 7-point scale, ranging from "not at all" to "extremely". These 12 items will be asked for the "first cigarette smoked", "cigarette immediately after a meal", and "all other cigarettes." The e-cigarette version of this questionnaire (mECEQ-E) will also be used. Baseline, Week 1, Week 2, Week 4, Week 8, Week 12
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Adherence to Anti- Retroviral Therapy (ART) Among People Living With Human Immunodeficiency Virus (HIV) Phase 4
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04617444 - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function N/A
Completed NCT02796391 - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes Phase 2
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Not yet recruiting NCT05188287 - A Culturally Tailored Smartphone Application for African American Smokers N/A
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT03187730 - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants Phase 4
Completed NCT03474783 - To Explore the Factors Affecting the Effectiveness of Smoking Cessation N/A
Completed NCT04635358 - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center N/A
Terminated NCT03670264 - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation N/A
Completed NCT02997657 - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02905656 - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit N/A
Completed NCT02562521 - A Smoking Cessation Intervention for Yale Dining Employees Phase 4
Completed NCT02239770 - Pharmacokinetics of Nicotine Film in Smokers N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A
Enrolling by invitation NCT02218944 - Smoking Response Inhibition Training N/A
Completed NCT03002883 - STAND Community College Tobacco Cessation Trial N/A